Navigating the Orexin Pathway: From Insomnia Antagonists to Narcolepsy Agonists — Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypocretin Receptor 2 Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HCRTR2 (Orexin Receptor Type 2) drug discovery. Because HCRTR2 is a complex multi-pass transmembrane GPCR, functional cell-based assays are the only robust method to preserve its native conformation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | HCRTR2 Lentivirus Premade Particles Full-length ORF, CMV promoter, Puro selection. For stable GPCR cell line construction preserving native conformation. Sequence Verified. |
View HCRTR2 Products |
| Expression Vector | HCRTR2 Promise-ORF Full-length ORF for transient transfection. Endotoxin Controlled. |
View HCRTR2 Products |
| Antigen | HCRTR2 Membrane Preparation HEK293 Overexpressing Cell Lysate, Native Glycosylation. Suitable for binding assays. |
View HCRTR2 Products |
| Benchmark Ab | Anti-HCRTR2 Reference Antibody Recombinant rabbit monoclonal, Sequence Verified, for flow cytometry, ICC, and western blot validation. |
View HCRTR2 Products |
| Validator | HCRTR2 siRNA Set (3 Unique Targets) For specific knockdown verification in native cell lines. >85% knockdown efficiency guaranteed. |
View HCRTR2 Products |
| Selectivity Control | HCRTR1 (Orexin Receptor 1) Orthologous GPCR for off-target screening. Critical for HCRTR2-selective agonist programs. |
View HCRTR1 Products |
| Ligand Control | HCRT (Prepro-orexin / Orexin) Endogenous neuropeptide ligand. For competition binding and functional validation. |
View HCRT Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-mediated stable cell lines in HEK293 preserve native glycosylation and 7-TM topology. High-titer Lentivirus enables stable cell line generation, maintaining functional transmembrane structures. |
| Subtype Selectivity (OX2R vs OX1R) | Sequence-verified Promise-ORFs for both HCRTR1 and HCRTR2 allow rigorous parallel selectivity assays. Matched HCRTR1 and HCRTR2 Lentivirus Pairs with identical expression levels (MOI optimized) for direct head-to-head compound screening. |
| Lack of Validated Tools for Functional Readouts | Full-length human, cyno, mouse, and rat HCRTR2 ORF clones available. Sequence Verified by NGS, >99% identity to reference genome. Supports cross-species translational models. |
| False Positives in Screening | Included siRNA sets enable strict genetic validation of GPCR target engagement. |
| Functional Validation (Agonist Mode) | Calcium Flux Ready: Pre-validated stable lines expressing Calcium biosensor (GCaMP6s) optional. Eliminate transient transfection variability. |
Live HCRTR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The HCRTR2 therapeutic paradigm is undergoing a radical inversion. Following the success of dual orexin receptor antagonists (DORAs) for insomnia (Suvorexant, Lemborexant, Daridorexant), the field is pivoting toward selective HCRTR2 agonism for narcolepsy type 1 (NT1), where orexin neuron loss creates a deficiency state. First-generation small molecule agonists have reached late-stage clinical trials: Takeda's TAK-861 (oral, Phase 3) leads the pack, while Alkermes (ALKS 2680) and Centessa Pharmaceuticals (CRN-00808, partnered with Novo Nordisk) follow with differentiated mechanisms. However, earlier agents like Takeda's TAK-994 (oral agonist) reached Phase 2 but were discontinued due to safety signals (hepatic toxicity), highlighting the critical need for improved safety profiles. The next wave of R&D targets extended half-life, improved blood-brain barrier (BBB) penetrance, biased signaling (minimizing desensitization), and strict receptor subtype selectivity (sparing HCRTR1 to avoid anxiety-related side effects). Precise subtype selectivity and biased signaling remain the critical bottlenecks for next-generation drug safety and efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Takeda, Alkermes, Centessa/Novo Nordisk, Jazz Pharma | Narcolepsy Type 1 (NT1), Excessive Daytime Sleepiness (EDS) | Calcium Flux & Beta-arrestin Bias (Need stable GPCR cell lines with consistent expression and bias readout) |
| DORA (Small Molecule Antagonist) | Merck, Eisai, Idorsia | Insomnia | Selectivity Panel (Need HCRTR1 vs HCRTR2 discrimination assays) |
| Peptide Agonist / Biologic | Takeda (former TAK-925), Orexia Therapeutics | Narcolepsy, Hypersomnia, Cognitive Impairment | Internalization Assay & Receptor Binding (Need high-purity HCRT ligand and surface expression validation) |
| Gene Therapy | Preclinical Academia | Narcolepsy (Orexin neuron replacement) | Receptor Expression Validation (Need anti-HCRTR2 antibodies for IHC and detection) |